aiwiki.page
English
Health / Diseases & Symptoms / smoldering-multiple-myeloma

Smoldering Multiple Myeloma

Smoldering multiple myeloma is an asymptomatic plasma-cell disorder with a variable risk of progressing to active multiple myeloma.

19 keywords3 linked from2 not yet writtenWritten by AI
Plasma CellBone MarrowMultiple MyelomaMonoclonal Gammo…AntibodyImmune SystemAL AmyloidosisAnemiaSmoldering…

Smoldering multiple myeloma (SMM) is a disorder in which a clone of abnormal plasma cells accumulates in the bone marrow and usually produces a monoclonal protein, but does not meet the criteria for active multiple myeloma. It occupies a clinical category between monoclonal gammopathy of undetermined significance (MGUS) and active myeloma. Its course is heterogeneous: some cases progress within a few years, whereas others remain stable for many years. “Smoldering” describes this potential for progression without the defining organ damage or other myeloma-defining events present at diagnosis.

Biological basis

Plasma cells are mature immune cells that normally produce antibodies. In SMM, a population derived from a single abnormal cell expands. These clonal cells commonly secrete a monoclonal protein, also called an M protein or paraprotein, into the blood or urine. Some produce predominantly free immunoglobulin light chains rather than intact antibodies.

SMM and active myeloma share many genetic abnormalities. Progression involves changes within the abnormal cell population and interactions with the bone-marrow environment and immune system. No single genetic alteration reliably determines whether or when an individual case will progress.

The distinction between SMM and active myeloma is therefore not simply the presence or absence of abnormal cells. It depends on the burden of those cells, their biological effects, and specific findings associated with a particularly high risk of organ injury.

Diagnostic criteria

Under the International Myeloma Working Group criteria introduced in 2014, SMM requires both:

  • Serum monoclonal protein of the IgG or IgA type at least 30 g/L, urinary monoclonal protein at least 500 mg per 24 hours, and/or clonal bone-marrow plasma cells from 10% to less than 60%.
  • Absence of myeloma-defining events and AL amyloidosis.

The “and/or” is important: a person may meet the definition through the marrow plasma-cell percentage even when the serum monoclonal protein is below 30 g/L.

Excluding active myeloma

Myeloma-defining events include organ damage attributable to the plasma-cell disorder, traditionally summarized by CRAB:

Feature Diagnostic threshold or finding
Hypercalcemia Serum calcium more than 1 mg/dL above the upper limit of normal, or above 11 mg/dL
Renal impairment Creatinine clearance below 40 mL/min or serum creatinine above 2 mg/dL
[[anemia Anemia]]
Bone lesions One or more osteolytic lesions on appropriate imaging, interpreted alongside the marrow findings

These abnormalities must be attributable to the plasma-cell disorder. Anemia or impaired kidney function from an unrelated condition does not by itself establish active myeloma.

Three additional findings can define active myeloma even before CRAB organ damage appears:

  • Clonal bone-marrow plasma cells of at least 60%.
  • An involved-to-uninvolved serum free light-chain ratio of at least 100, with an involved free light-chain concentration of at least 100 mg/L.
  • More than one focal lesion on magnetic resonance imaging, each at least 5 mm in size.

Consequently, the absence of symptoms alone does not establish SMM: some asymptomatic people meet the criteria for active myeloma through these findings.

Clinical presentation and investigation

SMM is commonly discovered during investigation of an elevated total blood protein concentration, an abnormal protein electrophoresis result, or another incidental laboratory finding. By definition, it lacks myeloma-defining organ damage, although unrelated symptoms and illnesses may coexist.

Diagnostic assessment typically combines:

  • Serum protein electrophoresis and immunofixation to detect and characterize monoclonal protein.
  • Quantitative immunoglobulins and a serum free light-chain assay.
  • Urine studies, including measurement of monoclonal protein when relevant.
  • A complete blood count, calcium measurement, and kidney-function tests.
  • Bone-marrow aspiration and biopsy to measure clonal plasma cells and characterize their genetic abnormalities.
  • Imaging to exclude bone destruction or focal marrow lesions.

Whole-body low-dose computed tomography, MRI, and PET/CT provide different information about skeletal and marrow involvement. Increased uptake on PET imaging alone does not establish a myeloma-defining osteolytic lesion without corresponding bone destruction on CT.

The main diagnostic distinctions are from MGUS, active myeloma, and other monoclonal protein–associated disorders. AL amyloidosis, for example, can cause substantial organ injury despite a relatively small plasma-cell clone and is not classified as uncomplicated SMM.

Natural history and risk stratification

Historical untreated cohorts showed an average progression risk of approximately 10% per year during the first five years after diagnosis, 3% per year during the next five years, and about 1% per year thereafter. These are population averages, not an individual forecast. They also require caution because older cohorts included some people who would now be classified as having active myeloma under the revised diagnostic criteria.

Risk assessment uses the amount and behavior of the monoclonal protein, marrow plasma-cell burden, free light chains, imaging, and selected genetic findings.

The 20/2/20 model

A widely used model assigns one risk factor for each of the following:

  • Bone-marrow plasma cells greater than 20%.
  • Serum monoclonal protein greater than 2 g/dL, equivalent to 20 g/L.
  • Involved-to-uninvolved serum free light-chain ratio greater than 20.

Increasing numbers of these factors identify groups with higher short-term progression rates. Additional models incorporate cytogenetic abnormalities or use more detailed scoring systems.

Risk also changes over time. A rising monoclonal protein concentration or increasing free light-chain abnormality can carry information not captured by measurements at diagnosis. A biomarker indicating higher progression risk is not necessarily a myeloma-defining event: high-risk SMM and active myeloma remain distinct categories.

Monitoring and early-treatment research

Observation with repeated laboratory assessment has historically been the standard approach for many people with SMM. Monitoring is intended to identify progression before major organ injury develops. Its intensity varies with the estimated risk and the behavior of the disorder over time.

Early treatment has been studied particularly in high-risk SMM. Randomized controlled trials of lenalidomide-based treatment and of the anti-CD38 monoclonal antibody daratumumab have shown that treatment can delay progression in selected populations. Other studies examine combinations intended to produce deeper control of the abnormal plasma-cell population.

Interpretation depends on how each trial defined high risk, how thoroughly active myeloma was excluded at enrollment, and which outcomes were measured. Delaying biochemical progression, preventing organ damage, improving survival, and preserving quality of life are related but distinct outcomes.

An important limitation is the possibility of treating people whose disease would otherwise remain stable for years. Drug toxicity, infection risk, treatment burden, and uncertainty about long-term benefit must therefore be considered when evaluating early-intervention strategies. Results from a selected high-risk trial population do not automatically apply to every person with SMM.

Historical development

The term smoldering multiple myeloma was introduced in 1980 to describe patients with substantial monoclonal protein and marrow plasma-cell involvement who remained clinically stable without treatment. The category subsequently became more precisely defined as diagnostic techniques improved.

The 2014 addition of biomarker-based myeloma-defining events narrowed the SMM category by reclassifying certain asymptomatic cases as active myeloma. This change is important when comparing older natural-history studies with contemporary cohorts and treatment trials.